Pharmaceutical Commercialization

We partner with small and emerging pharmaceutical companies to bring end-to-end commercialization capabilities with practical solutions. Our goal is to help them mitigate risks and optimize results.

The U.S. pharmaceutical market is difficult for small, emerging manufacturers to navigate due to:

• An increasingly complicated channel structure

• Buyer consolidation

• More and faster FDA approvals

• More competitors with sophisticated capabilities

Too often, new companies make:

• Commercial decisions without clear visibility to the revenue, margin, and cash impacts  

• Operating decisions based on faulty assumptions

• Business decisions based on overly optimistic performance capabilities

The net results are typically:

• Poor decisions which translate into unacceptable performance

• Manufacturers spending too much on support services, running their businesses sub-optimally due to lack of timely decision support, or both